Skip to content

PRESS RELEASES


PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Integra’s DuraSeal® Dural Sealant Saves Healthcare Costs According to an Economic Evaluation Published in the Journal of Comparative Effectiveness Research
The health economic analysis, conducted in five European countries, shows that hospitals can reduce costs of cerebrospinal fluid leaks after posterior cranial fossa surgeries by using DuraSeal dural sealant instead of fibrin glue PRINCETON, N.J., Nov.
View HTML
Toggle Summary Integra LifeSciences Reports Third Quarter 2024 Financial Results
PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2024. Third Quarter 2024 Highlights Third quarter revenues of $380.8
View HTML
Toggle Summary Integra LifeSciences Announces Appointment of Mojdeh Poul as President and Chief Executive Officer
A proven healthcare executive with deep global expertise and a distinguished record in business strategy and execution, portfolio transformation, value-creating innovation, commercial excellence, and leadership development PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences
View HTML
Toggle Summary Integra LifeSciences to Host Third Quarter 2024 Financial Results Conference Call on November 4, 2024
PRINCETON, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, will release third quarter 2024 financial results on Monday, November 4, 2024, prior to the market open. In conjunction with the earnings
View HTML
Toggle Summary Integra LifeSciences to Present at the 22nd Annual Morgan Stanley Healthcare Conference
PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, announced today that Lea Knight, chief financial officer will present at the Morgan Stanley Healthcare conference on September 6, 2024 at
View HTML
Toggle Summary Integra LifeSciences to Present at the 2024 Wells Fargo Healthcare Conference
PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, announced today that Lea Knight, chief financial officer, will present at the Wells Fargo Healthcare conference on September 4, 2024 at 1:30pm
View HTML
Toggle Summary Integra LifeSciences Continues to Make Progress on Its ESG Strategy
The company published its third ESG report, underscoring its values and commitment to restoring lives PRINCETON, N.J., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Company (NASDAQ: IART), a leading global medical technology company, today issued its latest Environmental, Social
View HTML
Toggle Summary Integra LifeSciences Reports Second Quarter 2024 Financial Results
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2024. Second Quarter 2024 Highlights Second quarter revenues of $418.2
View HTML
Toggle Summary Integra LifeSciences Provides Updated Plans for Its Manufacturing Facility in Braintree, Massachusetts
The company plans on operationalizing this new state-of-the-art facility in the first half of 2026 PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, is announcing its plans to restart the
View HTML
Toggle Summary Integra LifeSciences to Host Second Quarter 2024 Financial Results Conference Call on July 29, 2024
PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, will release second quarter 2024 financial results on Monday, July 29, 2024, prior to the market open. In conjunction with the earnings release,
View HTML
Toggle Summary Integra LifeSciences to Present at the 2024 Bank of America Healthcare Conference
PRINCETON, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, announced today that Lea Knight, chief financial officer will present at the 2024 Bank of America Healthcare conference on Tuesday, May 14, 2024
View HTML
Toggle Summary Integra LifeSciences Reports First Quarter 2024 Financial Results
PRINCETON, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2024. First Quarter 2024 Highlights First quarter revenues of $368.9
View HTML
Toggle Summary Integra LifeSciences to Spotlight CereLink® Intracranial Pressure (ICP) Monitoring System at the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting
Visit the Codman Specialty Surgical booth to learn how the CereLink ICP Monitoring System provides patients with uncompromised advanced continuous ICP monitoring. PRINCETON, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical
View HTML
Toggle Summary Integra LifeSciences to Reschedule the First Quarter 2024 Financial Results Conference Call to May 6, 2024
PRINCETON, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, today announced that it has rescheduled the release of the Company’s first quarter 2024 financial results to Monday, May 6, 2024. In
View HTML
Toggle Summary Integra LifeSciences Completes the Acquisition of Acclarent, Inc.
PRINCETON, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of Acclarent, Inc. , a pioneer in ear, nose and throat (ENT) surgical
View HTML